981 related articles for article (PubMed ID: 19412164)
21. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A.
Pulvino M; Liang Y; Oleksyn D; DeRan M; Van Pelt E; Shapiro J; Sanz I; Chen L; Zhao J
Blood; 2012 Aug; 120(8):1668-77. PubMed ID: 22791293
[TBL] [Abstract][Full Text] [Related]
22. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
23. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.
Kloo B; Nagel D; Pfeifer M; Grau M; Düwel M; Vincendeau M; Dörken B; Lenz P; Lenz G; Krappmann D
Proc Natl Acad Sci U S A; 2011 Jan; 108(1):272-7. PubMed ID: 21173233
[TBL] [Abstract][Full Text] [Related]
24. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Lenz G; Davis RE; Ngo VN; Lam L; George TC; Wright GW; Dave SS; Zhao H; Xu W; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Chan WC; Staudt LM
Science; 2008 Mar; 319(5870):1676-9. PubMed ID: 18323416
[TBL] [Abstract][Full Text] [Related]
26. Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.
Liu F; Karube K; Kato H; Arita K; Yoshida N; Yamamoto K; Tsuzuki S; Kim W; Ko YH; Seto M
Int J Clin Exp Pathol; 2012; 5(5):436-41. PubMed ID: 22808296
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20).
Kim SW; Ramasamy K; Bouamar H; Lin AP; Jiang D; Aguiar RC
Proc Natl Acad Sci U S A; 2012 May; 109(20):7865-70. PubMed ID: 22550173
[TBL] [Abstract][Full Text] [Related]
28. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.
Novak U; Rinaldi A; Kwee I; Nandula SV; Rancoita PM; Compagno M; Cerri M; Rossi D; Murty VV; Zucca E; Gaidano G; Dalla-Favera R; Pasqualucci L; Bhagat G; Bertoni F
Blood; 2009 May; 113(20):4918-21. PubMed ID: 19258598
[TBL] [Abstract][Full Text] [Related]
29. Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.
Calado DP; Zhang B; Srinivasan L; Sasaki Y; Seagal J; Unitt C; Rodig S; Kutok J; Tarakhovsky A; Schmidt-Supprian M; Rajewsky K
Cancer Cell; 2010 Dec; 18(6):580-9. PubMed ID: 21156282
[TBL] [Abstract][Full Text] [Related]
30. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.
Dong G; Chanudet E; Zeng N; Appert A; Chen YW; Au WY; Hamoudi RA; Watkins AJ; Ye H; Liu H; Gao Z; Chuang SS; Srivastava G; Du MQ
Clin Cancer Res; 2011 Mar; 17(6):1440-51. PubMed ID: 21266526
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.
Ma Y; Liao Z; Xu Y; Zhong Z; Wang X; Zhang F; Chen S; Yang L; Luo G; Huang X; Huang S; Wu X; Li Y
Eur J Med Res; 2014 Nov; 19(1):62. PubMed ID: 25384343
[TBL] [Abstract][Full Text] [Related]
32. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
[TBL] [Abstract][Full Text] [Related]
33. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
34. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
[TBL] [Abstract][Full Text] [Related]
35. LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.
Jo T; Nishikori M; Kogure Y; Arima H; Sasaki K; Sasaki Y; Nakagawa T; Iwai F; Momose S; Shiraishi A; Kiyonari H; Kagaya N; Onuki T; Shin-Ya K; Yoshida M; Kataoka K; Ogawa S; Iwai K; Takaori-Kondo A
Blood; 2020 Aug; 136(6):684-697. PubMed ID: 32325488
[TBL] [Abstract][Full Text] [Related]
36. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.
Schmidt A; Schmitz R; Giefing M; Martin-Subero JI; Gesk S; Vater I; Massow A; Maggio E; Schneider M; Hansmann ML; Siebert R; Küppers R
Genes Chromosomes Cancer; 2010 Sep; 49(9):803-9. PubMed ID: 20607853
[TBL] [Abstract][Full Text] [Related]
37. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.
Li L; Xu-Monette ZY; Ok CY; Tzankov A; Manyam GC; Sun R; Visco C; Zhang M; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Wang J; Parsons BM; Winter JN; Piris MA; Pham LV; Medeiros LJ; Young KH
Oncotarget; 2015 Sep; 6(27):23157-80. PubMed ID: 26324762
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.
Paik JH; Go H; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2013 Sep; 54(9):1934-41. PubMed ID: 23327292
[TBL] [Abstract][Full Text] [Related]
40. CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.
Jin X; Shi Q; Li Q; Zhou L; Wang J; Jiang L; Zhao X; Feng K; Lin T; Lin Z; Zhuang H; Yang J; Hu C; Zhang L; Shen L; Lu Y; Zhu J; Wang H; Qi H; Meng X; Xi Y; Pan J; Fang S; Tian H; Zhou C; Zhang P; Gao K; Zhao SM; Li Y; Gong Z; Wang C
Leukemia; 2020 May; 34(5):1305-1314. PubMed ID: 31776466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]